ACUTE INTERVENTION MANAGEMENT STRATEGIES (AIMS)

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Current treatment for acute wheezing episodes during a respiratory illness includes bronchodilators. If symptoms continue or worsen, oral steroids are added. Clinical experience has shown that chest symptoms may develop late in the illness and often respond poorly even when oral steroids are added at the onset of wheezing (2-3 days after onset of cold symptoms). These factors contribute to a high rate of ER visits and hospitalizations. With this protocol, we propose to start treatment of inhaled budesonide or oral montelukast at the onset of a respiratory tract illness to decrease the amount of wheezing during the illness, increase the number of symptom-free days, and prolong the time to initiation of oral steroids. Healthy males and females (12-59 months) of diverse ethnicities were invited to join this study. Subjects must be relatively healthy other than having moderate-severe intermittent wheezing related to respiratory illnesses.